Long-Term Effectiveness And Safety Of CP-690,550 For The Treatment Of Rheumatoid Arthritis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT00413699

Recruitment Status : Completed

First Posted : December 20, 2006

Results First Posted : March 27, 2018

Last Update Posted : October 30, 2018

View this study on Beta.ClinicalTrials.gov

Sponsor:

Information provided by (Responsible Party):

Pfizer

Study Description

Brief Summary:

The purpose of this study is to determine the long-term effectiveness and safety of CP-690,550 for the treatment of rheumatoid arthritis. Subjects are eligible for this study only after participating in another "qualifying" study of CP-690,550

A sub-study will be conducted within the A3921024 study, this study will evaluate the immune response to pneumococcal and influenza vaccines in patients receiving CP-690,550

Condition or disease	Intervention/treatment	Phase
Arthritis, Rheumatoid	Drug: CP-690,550	Phase 3

Study Design

Layout table for study information

Study Type :	Interventional (Clinical Trial)
Actual Enrollment :	4488 participants
Allocation:	Non-Randomized
Intervention Model:	Parallel Assignment
Masking:	None (Open Label)
Primary Purpose:	Treatment
Official Title:	A Long-term, Open-label Follow-up Study Of Tofacitinib (Cp-690,550) For Treatment Of Rheumatoid Arthritis
Actual Study Start Date :	February 5, 2007
Actual Primary Completion Date :	November 30, 2016
Actual Study Completion Date :	October 26, 2017

Resource links provided by the National Library of Medicine

MedlinePlus Genetics related topics: Rheumatoid arthritis

MedlinePlus related topics: Arthritis Rheumatoid Arthritis

U.S. FDA Resources

Arms and Interventions

Arm	Intervention/treatment
Experimental: Open-Label Active Treatment Enrolled from Phase 2 Patients enrolling from Phase 2 studies	Drug: CP-690,550 5 mg PO BID open label; may increase to 10 mg PO BID to provide greater control of RA if no related AEs are present. May be off study drug temporarily for up to 28 days for mild to moderate AEs.
Experimental: Open-Label Active Treatment Enrolled from Phase 3 Patients enrolling from Phase 3 studies	Drug: CP-690,550 10 mg PO BID open label; may decrease to 5 mg PO BID for mild to moderate AEs. May be off study drug temporarily for up to 28 days for mild to moderate AEs.

Outcome Measures

Primary Outcome Measures :

Initial Period: Primary Endpoints Were Standard Laboratory Safety Data (Chemistry, Hematology, Etc.) and Adverse Event (AE) Reports [ Time Frame: Includes laboratory test abnormality data for all visits and adverse event data up to 999 days after last dose of study drug ]
Treatment-emergent non serious AEs by System Organ Class (SOC) (all causalities) and Laboratory Test Abnormalities (without regard to baseline) The stated number of participants analyzed was the total number of participants in each group (AEs). The actual number of participants analyzed for each laboratory parameter varied, and is provided for each.

Abs=absolute; ALT=alanine aminotransferase; AST=aspartate aminotransferase; ESR=erythrocyte sedimentation rate; GGT=gamma glutamyl transferase; hgb=hemoglobin; HDL=high density lipids; LDL=low density lipids; LLN=lower limit of normal; qual=qualitative; Tot=total; ULN=upper limit of normal; WBC=white blood cell
Extension Period: Number of Participants With Treatment Emergent Adverse Events (AEs), Serious Adverse Events (SAEs) [ Time Frame: Baseline (Day 1 at Entry of Extension Period) up to 28 days after last study drug dose in Extension Period (13 Months) ]
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. A treatment emergent AE was defined as an event that emerged during the treatment period that was absent before treatment, or worsened during the treatment period relative to the pretreatment state. AEs included both serious and non-serious adverse events.
Extension Period: Number of Participants With Laboratory Test Abnormalities [ Time Frame: Baseline (Day 1 at Entry of Extension Period) up to 28 days after last study drug dose in Extension Period (13 Months) ]
Criteria for laboratory abnormalities: hemoglobin (Hg), hematocrit, red blood cell (RBC), high density lipoprotein (HDL) cholesterol:<0.8*lower limit of normal (LLN), platelet<0.5*LLN/>1.75*upper limit of normal (ULN), white blood cell (WBC)<0.6*LLN/>1.5*ULN, lymphocyte, neutrophil, protein, albumin <0.8*LLN/>1.2*ULN, basophil, eosinophil, monocyte, low density lipoprotein (LDL) cholesterol: >1.2*ULN; bilirubin>1.5*ULN, aspartate amino transferase(AT), alanine AT, gammaglutamyl transferase, alkaline phosphatase:>3.0*ULN; blood urea nitrogen, creatinine, cholesterol, triglyceride:>1.3*ULN; sodium <0.95*LLN/>1.05*ULN, potassium, chloride, calcium, bicarbonate: <0.9*LLN/>1.1*ULN; glucose<0.6*LLN/>1.5*ULN; Urine (specific gravity<1.003/>1.030, pH<4.5/>8, glucose, ketone, protein, blood/Hg(>=1; RBC, WBC>=20; creatinine kinase>2*ULN).
Initial Period: The Long Term Safety and Tolerability of CP-690,550 5 Milligrams (mg) Twice Daily (BID) and 10 mg BID for the Treatment of Rheumatoid Arthritis [ Time Frame: Includes AEs for every visit and up to 999 days after last dose of study drug ]
Treatment-emergent AEs by SOC (all causalities) - all participants, by time. Data presented for Post Month 96 includes data up to and including Month 114.
Extension Period: Percentage of Participants With Adverse Events and Who Discontinued Treatment Due to Adverse Events to Assess Long-term Safety and Tolerability of Tofacitinib [ Time Frame: Baseline (Day 1 at Entry of Extension Period) up to Month 6 of Extension Period; Month 6 of Extension Period to Month 12 of Extension Period ]
Long term safety and tolerability of Tofacitinib was measured as following: percentage (%) of participants with AEs, percentage of participants who discontinued due to AEs. An AE is any untoward medical occurrence in participant who received study drug without regard to possibility of causal relationship.

Secondary Outcome Measures :

Initial Period: Percentage of Patients With American College of Rheumatology (ACR) 20, 50, and 70 Responses [ Time Frame: Every visit until study completion ]
The stated number of participants analyzed was the total number of participants in each group. The actual number of participants analyzed on each occasion varied, and is provided for each visit presented. ACR20 is defined as a 20% improvement from baseline in tender/painful joint count and swollen joint count, and at least 3 of the following 5 variables: Subject's Global Assessment of Arthritis, Physician's Global Assessment of Arthritis, Subject's Assessment of Arthritis Pain, Health Assessment Questionnaire - Disability Index, C-Reactive Protein (CRP). ACR50 is a 50% improvement and ACR70 a 70% improvement in these variables.
Extension Period: Percentage of Participants With American College of Rheumatology (ACR) 20, 50, and 70 Responses [ Time Frame: Month 3, 6, 9 and 12 of Extension Period ]
ACR20=20 percent (%) improvement from baseline (Month 0 at entry of Initial Period) in tender/painful joint count and swollen joint count, and in at least 3 of 5 variables: participant's global assessment of arthritis (PtGA), physician's global assessment of arthritis (PGA), participant's assessment of arthritis pain (PtA), HAQ-DI, C-reactive protein. ACR50 is a 50% improvement and ACR70 is a 70% improvement in these variables. PtGA: participant assessed overall disease activity, score: 0 (no arthritis) to 10 (extreme arthritis), higher score=more arthritis. PGA: physician judged participant's overall disease activity, score: 0 (no arthritis) to 10 (extreme arthritis), higher score=more arthritis. PtA: participant assessed arthritis pain by 100 millimeter (mm) visual analogue scale, score: 0 mm (no pain) to 100 mm (extreme pain), higher score=more pain. HAQ-DI: functional disability evaluation, score: 0 (no difficulty) to 3 (extreme difficulty), higher score=more disability.
Initial Period: Area Under American College of Rheumatology (ACR) n Curve [ Time Frame: Not applicable as no data were collected for this endpoint. ]
No data were collected for this endpoint because it was removed from the protocol in a previous amendment.
Initial Period: Disease Activity Score (DAS)28 (C-reactive Protein [CRP]) and DAS28 (Erythrocyte Sedimentation Rate [ESR]) [ Time Frame: Every visit until study completion ]
Descriptive statistics for DAS28-3 (CRP) and DAS28-4 (ESR). The stated number of participants analyzed was the total number of participants in each group. The actual number of participants analyzed on each occasion varied, and is provided for each visit presented.

DAS28 is a composite score, calculated using a mathematical formula, and is derived from the number of tender/painful joints (out of 28), number of swollen joints (out of 28), and a blood marker of inflammation (ESR or CRP). DAS28-4 also includes a score of general health in the formula.

The score range is from 0 to 9.4, with a higher score indicating more disease activity. A score of >5.1 indicates active disease, a score of ≤3.2 indicates low disease activity, and a score of <2.6 indicates disease remission.
Extension Period: Change From Baseline in Disease Activity Score (DAS) 28-3 C-Reactive Protein (CRP)(DAS28-3 CRP) and DAS28-4 Erythrocyte Sedimentation Rate (ESR)(DAS28-4 ESR) at Month 3, 6, 9 and 12 [ Time Frame: Baseline (Month 0 at the entry of Initial period); Month 3, 6, 9 and 12 of Extension Period ]
DAS28 is composite score, calculated using mathematical formula, derived from: 1) tender/painful joints count, out of 28 joints (TJC28), 2) swollen joints count, out of 28 joints (SJC28), 3) blood marker of inflammation (ESR [millimeter per hour] or CRP [milligram per liter]). DAS28-4 also include score of general health (GH). GH is general health or participants' global assessment of disease activity on 100 mm visual analog scale (GH score: 0 mm [very well] to 100 mm [extremely bad], higher scores = worse health condition). DAS28-3(CRP) = (0.56*sqrt[TJC28] + 0.28*sqrt[SJC28] + 0.36*ln[CRP+1]) *1.10 + 1.15) and DAS28-4(ESR) = (0.56*sqrt[TJC28] + 0.28*sqrt[SJC28] + 0.70*ln[ESR] + 0.014*GH), where sqrt = square root, ln = natural logarithm. DAS28-4 ESR and DAS28-3 CRP: score ranges from 0 (none) to 9.4 (extreme disease activity), with a higher score indicating more disease activity. Score of <=3.2 indicate low disease activity and score of <2.6 indicate disease remission.
Initial Period: Number (%) of Participants With DAS28-4 (ESR) and DAS28-3 (CRP) <2.6 and ≤3.2 [ Time Frame: Every visit until study completion ]
Percent participants with DAS28-4 (ESR) <2.6 and ≤3.2 and percent participants with DAS28-3 (CRP) <2.6 and ≤3.2. The stated number of participants analyzed was the total number of participants in each group. The actual number of participants analyzed on each occasion varied, and is provided for each visit presented.

DAS28 is a composite score, calculated using a mathematical formula, and is derived from the number of tender/painful joints (out of 28), number of swollen joints (out of 28), and a blood marker of inflammation (ESR or CRP). DAS28-4 also includes a score of general health in the formula.

The score range is from 0 to 9.4, with a higher score indicating more disease activity. A score of >5.1 indicates active disease, a score of ≤3.2 indicates low disease activity, and a score of <2.6 indicates disease remission.
Extension Period: Percentage of Participants With DAS28-4 (ESR) and DAS28-3 (CRP) Less Than (<) 2.6 and Less Than or (<=) 3.2 [ Time Frame: Baseline (Day 1 at the entry of Extension period); Month 3, 6, 9 and 12 of Extension Period ]
DAS28 is composite score, calculated using mathematical formula, derived from: 1) tender/painful joints count, out of 28 joints (TJC28), 2) swollen joints count, out of 28 joints (SJC28), 3) blood marker of inflammation (ESR [millimeter per hour] or CRP [milligram per liter]). DAS28-4 also include score of GH. GH is general health or participants' global assessment of disease activity on 100 mm visual analog scale (GH score: 0 mm [very well] to 100 mm [extremely bad], higher scores = worse health condition). DAS28-3(CRP) = (0.56*sqrt[TJC28] + 0.28*sqrt[SJC28] + 0.36*ln[CRP+1]) *1.10 + 1.15) and DAS28-4(ESR) = (0.56*sqrt[TJC28] + 0.28*sqrt[SJC28] + 0.70*ln[ESR] + 0.014*GH), where sqrt = square root, ln = natural logarithm. DAS28-4 ESR and DAS28-3 CRP: score range is from 0 (none) to 9.4 (extreme disease activity), with a higher score indicating more disease activity. Score of <=3.2 indicate low disease activity and score of <2.6 indicate disease remission.
Initial Period: Health Assessment Questionnaire - Disability Index (HAQ-DI) Score [ Time Frame: Every visit until study completion ]
Change from baseline by visit. HAQ-DI scores range from 0 to 3, where lower score implies less disease. A reduction from baseline in score indicates an improvement in condition. A clinically meaningful decrease from baseline is defined as a decrease of at least 0.22 units. The stated number of participants analyzed was the total number of participants in each group. The actual number of participants analyzed on each occasion varied, and is provided for each visit presented.
Extension Period: Change From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) Score at Month 3, 6, 9 and 12 [ Time Frame: Baseline (Month 0 at the entry of Initial Period); Month 3, 6, 9, and 12 of Extension Period ]
HAQ-DI assesses the degree of difficulty a participant has experienced during the past week in 8 categories of daily living activities: dressing/grooming; arising; eating; walking; reach; grip; hygiene; and other activities. Each activity category consisted of 2-3 questionnaire. Each questionnaire was scored on a 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Any activity that required assistance from another individual or required the use of an assistive device was adjusted to a score of 2 to represent a more limited functional status. Overall score was computed as the sum of total scores divided by the number of questionnaire answered. Total possible HAQ-DI score range: 0 (least difficulty) and 3 (extreme difficulty), where higher scores indicate more difficulty while performing daily living activities.
Initial Period: Short-Form-36 Health Survey (SF-36) Score [ Time Frame: Every visit until study completion ]
Change from Baseline for Physical Component and Mental Component Scores by visit. SF-36 is a health status measure of 8 general health domains, each scored on a 0 to 100 scale: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional, and mental health. These domains can be summarized as physical and mental component scores. The domain scores were "normed" and the resulting component scores treated as Z-scores with a scale of negative to positive infinity. A higher score implies less disease. The greater the change from baseline, the greater the improvement. The stated number of participants analyzed was the total number of participants in each group. The actual number of participants analyzed on each occasion varied, and is provided for each visit presented.
Initial Period: FACIT Fatigue Scale, EuroQol EQ 5D, Work Limitations Questionnaire, and RA Healthcare Resource Utilization Questionnaire (RA-HCRU) [ Time Frame: Every visit until study completion ]
Change from Baseline Scores for each: FACIT Fatigue Scale (score range 0 to 52, higher score indicates higher quality of life and an increase from baseline score indicates improvement), EuroQol EQ 5D (index values derived from a measure of central tendency and a measure of dispersion, an increase from baseline indicates improvement, score range 0 to 1), Work Limitations (WL) Physical Demands (covers ability to perform job tasks that involve bodily strength, a decrease from baseline indicates improvement, score range 0 to 100, higher scores indicating greater limitation), and RA Healthcare Resource Utilization Work Performance in Past 3 Months on Days Bothered by RA (assesses healthcare use over previous 3 months, a decrease from baseline indicates improvement, score range 0 to 10).

The stated number of participants analyzed was the total number of participants in each group. The actual number of participants analyzed on each occasion varied, and is provided for each visit presented.
Initial Period: Preservation of Joint Structure in Participants Who Had Baseline Radiographs Obtained in Their Qualifying Index Study [ Time Frame: Every 6 months until study completion ]
Modified Total Sharp Score per visit. Baseline score was the last available assessment from the index study. The Modified Total Sharp Score measures disease progression; increased scores indicate disease progression. Score range 0 (normal) to 448 (worst possible total score). The stated number of participants analyzed was the total number of participants in each group. The actual number of participants analyzed on each occasion varied, and is provided for each visit presented.

TSS=Total Sharp Score
Vaccine Sub-study. Percent Achieving a Satisfactory Humoral Response to the Pneumococcal Vaccine as Defined by ≥ 2-fold Increase in Antibody Concentrations [ Time Frame: From vaccine sub-study visit 2 (baseline) to sub-study visit 4 ]
Number (%) of participants achieving a satisfactory humoral response to the pneumococcal vaccine as defined by ≥2-fold increase in antibody concentration from vaccine sub-study visit 2 (vaccination baseline) in ≥6 of 12 anti-pneumococcal antigens (serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F) The number of participants was the number with a determinate antibody titer to the given vaccine antigen within the population.

95% CI is based on Clopper-Pearson exact method for response rate.
Vaccine Sub-study. Percent Achieving a Satisfactory Humoral Response to the Seasonal Influenza Vaccine as Defined by ≥ 4-fold Increase in Antibody Titers [ Time Frame: From vaccine sub-study visit 2 (baseline) to sub-study visit 4 ]
Number of participants achieving a satisfactory humoral response to the seasonal influenza vaccine as defined by ≥4-fold increase in antibody titers from visit 2 (vaccination baseline) in ≥2 of 3 influenza antigens (HAI B, HAI H1N1, and HAI H3N2) The number of participants was the number with a determinate antibody titer to the given vaccine antigen within the population.

95% CI is based on Clopper-Pearson exact method for response rate.
Vaccine Sub-study. Percentage of Participants Achieving Protective Antibody Titers to the Seasonal Influenza Vaccine as Measured by a Hemagglutination Inhibition (HI) Assay Titer of ≥ 1:40 in ≥ 2 of 3 Influenza Antigens at Vaccine Sub-study Visit 3 and 4 [ Time Frame: From vaccine sub-study visit 2 (baseline) to sub-study visit 4 ]
Number (%) of participants achieving protective antibody titers to the seasonal influenza vaccine as measured by an HAI assay titer of ≥1:40 in ≥2 of 3 influenza antigens measured at vaccine sub-study visits 3 and 4.

The number of participants was the number with a determinate antibody titer to the given vaccine antigen within the population.

95% CI is based on Clopper-Pearson exact method for response rate.
Vaccine Sub-study. Percentage of Participants Who Respond to Each of the 12 Pneumococcal Antigens as Defined by ≥ 2-fold Increase in Antibody Concentrations From Vaccine Sub-study Visit 2 (Vaccination Baseline) Measured at Vaccine Sub-study Visit 4 [ Time Frame: From vaccine sub-study visit 2 (baseline) to sub-study visit 4 ]
Number (%) of participants achieving a satisfactory humoral response to the pneumococcal vaccine as defined by ≥2-fold increase in antibody concentration from vaccine sub-study visit 2 (vaccination baseline) in ≥6 of 12 anti-pneumococcal antigens (serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F) The number of participants was the number with a determinate antibody titer to the given vaccine antigen within the population.

95% CI is based on Clopper-Pearson exact method for response rate.
Vaccine Sub-study. Percentage of Participants Who Respond to Each of the 3 Influenza Antigens as Defined by ≥ 4-fold Increase in Antibody Titers From Vaccine Sub-study Visit 2 (Vaccination Baseline) Measured at Vaccine Sub-study Visit 4 [ Time Frame: From vaccine sub-study visit 2 (baseline) to sub-study visit 4 ]
Number (%) of participants achieving a satisfactory humoral response to the seasonal influenza vaccine defined as ≥4-fold increase in antibody titers from visit 2 (vaccination baseline) in ≥2 of 3 influenza antigens (HAI B, HAI H1N1, and HAI H3N2).

The number of participants was the number with a determinate antibody titer to the given vaccine antigen within the population.

95% CI is based on Clopper-Pearson exact method for response rate.
Vaccine Sub-study. Fold Increase of Anti-pneumococcal Antibody Levels to Each of the 12 Pneumococcal Antigens Above Vaccination Baseline Values (Vaccine Sub-study Visit 2) at Vaccine Sub-study Visit 4 [ Time Frame: From vaccine sub-study visit 2 (baseline) to sub-study visit 4 ]
Geometric Mean Fold Increase From Baseline of Pneumococcal Antigens Measured at Visit 4.

n was the number of participants with valid and determinate assay results for the specified serotype at the given visit.

The stated number of participants analyzed was the total number of participants. The actual number of participants analyzed for some serotypes varied, and is provided where it differed from the total number of participants.

Confidence Intervals (CIs) were back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.
Vaccine Sub-study. Fold Increase of Anti-influenza Antibody Levels to Each of the 3 Influenza Antigens Above Vaccination Baseline Values (Vaccine Sub-study Visit 2) at Vaccine Sub-study Visit 4 [ Time Frame: From vaccine sub-study visit 2 (baseline) to sub-study visit 4 ]
Geometric Mean Fold Increase From Baseline of Influenza Antigens Measured at Visit 4.

n was the number of participants with valid and determinate assay results for the specified HAI strain at the given visit.

Confidence Intervals (CIs) were back transformations of a CI based on the Student t distribution for the mean logarithm of the titers.
Vaccine Sub-study. Concentrations of Anti-pneumococcal Antibodies at Vaccine Sub-study Visit 3 and 4 [ Time Frame: From vaccine sub-study visit 2 (baseline) to sub-study visit 4 ]
Mean pneumococcal concentrations (ug/mL) at vaccine baseline (visit 2) and post-vaccination visits (visits 3 and 4) by serotype. The stated number of participants analyzed was the total number of participants in each group. The actual number of participants analyzed for each serotype varied, and is provided for each individually.

ug/mL=micrograms per milliliter
Vaccine Sub-study. Titers of Anti-influenza Antibodies at Vaccine Sub-study Visit 3 and 4 [ Time Frame: From vaccine sub-study visit 2 (baseline) to sub-study visit 4 ]
Mean influenza antibody titers at visits 3 and 4.

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information

Ages Eligible for Study:	18 Years and older (Adult, Older Adult)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Subjects who have participated in a randomized "qualifying" study of CP-690,550 for the treatment of rheumatoid arthritis

Vaccine sub-study visit

Subjects actively participating in Study A3921024 must have completed at least 3 months of continuous 10 mg BID CP-690,550 treatment in A3921024 as defined by >80% compliance with prescribed dose consumption of CP-690,550 over the previous 3 months.

Exclusion Criteria:

Serious medical conditions that would make treatment with CP-690,550 potentially unsafe

Vaccine sub-study visit

Any documented influenza or pneumococcal infection within the last 3 months prior to randomization in this study
Received any vaccine within 1 month prior to randomization in this study
Received an influenza vaccine within 6 months or a pneumococcal vaccine within 5 years of randomization in this study.

Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00413699

Locations

Show 469 study locations

Layout table for location information

United States, Alabama
University of Alabama at Birmingham
Birmingham, Alabama, United States, 35294
Rheumatology Associates of North Alabama, PC
Huntsville, Alabama, United States, 35801
United States, Arizona
Arthrocare, Arthritis Care & Research, PC
Gilbert, Arizona, United States, 85234
Arizona Arthritis & Rheumatology Associates, P.C.
Phoenix, Arizona, United States, 85032
Radiant Research, Inc.
Scottsdale, Arizona, United States, 85251
Catalina Pointe Clinical Research
Tucson, Arizona, United States, 85704
United States, Arkansas
CHI St. Vincent Medical Group Hot Springs
Hot Springs, Arkansas, United States, 71913
NEA Baptist Clinic
Jonesboro, Arkansas, United States, 72401
Osborne Research Center, LLC
Little Rock, Arkansas, United States, 72201
Little Rock Diagnostic Clinic, PA
Little Rock, Arkansas, United States, 72205
United States, California
Med Investigations, Inc.
Fair Oaks, California, United States, 95628
Talbert Medical Group
Huntington Beach, California, United States, 92646
University of California San Diego Center for Innovative Therapy
La Jolla, California, United States, 92093
Keck Medicine of USC
Los Angeles, California, United States, 90033
University of Southern California (USC) Norris Comprehensive Cancer Center-
Los Angeles, California, United States, 90033
University of Southern California (USC) Norris Comprehensive Cancer Center
Los Angeles, California, United States, 90033
Ronald Reagan UCLA Medical Center, Drug Information Center
Los Angeles, California, United States, 90095-6984
University of California Los Angeles
Los Angeles, California, United States, 90095
Stanford University School of Medicine
Palo Alto, California, United States, 94304
Office of Anupama Bhat, MD
Roseville, California, United States, 95661
San Diego Arthritis Medical Clinic
San Diego, California, United States, 92108
Pacific Arthritis Center Medical Group
Santa Maria, California, United States, 93454
Stanford Health Services - Medical Specialty Clinics
Stanford, California, United States, 94305
Inland Rheumatology Clinical Trials, Inc.
Upland, California, United States, 91786
United States, Colorado
Boulder Medical Center, PC
Boulder, Colorado, United States, 80304
Arthritis Associates and Osteoporosis Center of Colorado Springs
Colorado Springs, Colorado, United States, 80910
United States, Connecticut
University of Connecticut Health Center
Farmington, Connecticut, United States, 06030-5353
Arthritis & Osteoporosis Center, PC
Hamden, Connecticut, United States, 06518
New England Research Associates, LLC
Trumbull, Connecticut, United States, 06611
United States, Delaware
Delaware Arthritis and Osteoporosis Center
Newark, Delaware, United States, 19713
United States, Florida
Arthritis and Rheumatic Disease Specialties
Aventura, Florida, United States, 33180
Allergy, Asthma, Arthritis, & Lung
Daytona Beach, Florida, United States, 32114
Physicians Research Alliance LLC
DeBary, Florida, United States, 32713
Southeastern Arthritis Center
Gainesville, Florida, United States, 32607
Southeastern Imaging and Diagnostics
Gainesville, Florida, United States, 32607
Southeastern Integrated Medical PL d/b/a Florida Medical Research Institute
Gainesville, Florida, United States, 32607
Southeastern Integrated Medical, PL, d/b/a Florida Medical Research Institute
Gainesville, Florida, United States, 32607
Jacksonville Center for Clinical Research
Jacksonville, Florida, United States, 32216
Florida Arthritis Center, P.L.
Lake Mary, Florida, United States, 32746
BayCare Outpatient Imaging at Bardmoor
Largo, Florida, United States, 33777
Center for Arthritis and Rheumatic Diseases
Miami, Florida, United States, 33173
Jeffrey Alper MD Research
Naples, Florida, United States, 34102
Suncoast Clinical Research, Inc.
New Port Richey, Florida, United States, 34652
Ocala Rheumatology Research Center
Ocala, Florida, United States, 34474
Dr. Jeffrey E. Poiley, MD , Office of
Orlando, Florida, United States, 32804
Millennium Research
Ormond Beach, Florida, United States, 32174
DMI Research, Inc.
Pinellas Park, Florida, United States, 33782
Florida Arthritis & Osteoporosis Center
Port Richey, Florida, United States, 34668
Gulf Coast Medical Center
Port Richey, Florida, United States, 34668
Suncoast Medical Clinic
Saint Petersburg, Florida, United States, 33782
Arthritis & Rheumatic Care Center
South Miami, Florida, United States, 33143
Miami Research Associates
South Miami, Florida, United States, 33143
West Broward Rheumatology Associates, Inc.
Tamarac, Florida, United States, 33321
BayCare Medical Group, Inc
Tampa, Florida, United States, 33614
Lovelace Scientific Resources
Venice, Florida, United States, 34292
Venice Arthritis Center
Venice, Florida, United States, 34292
Florida Medical Clinic, P.A.
Zephyrhills, Florida, United States, 33542
United States, Georgia
Arthritis and Rheumatology of Georgia P.C.
Atlanta, Georgia, United States, 30342
Jeffrey D. Lieberman, MD, PC
Decatur, Georgia, United States, 30333
Marietta Rheumatology Associates
Marietta, Georgia, United States, 30060
United States, Idaho
St. Luke's Clinic - Rheumatology
Boise, Idaho, United States, 83702
St. Luke's Clinic
Boise, Idaho, United States, 83702
St. Luke's Intermountain Research Center
Boise, Idaho, United States, 83702
Institute of Arthritis Research
Idaho Falls, Idaho, United States, 83404
St. Luke's Clinic - Rhematology
Meridian, Idaho, United States, 83642
United States, Illinois
Loyola University Medical Center
Maywood, Illinois, United States, 60153
Illinois Bone and Joint Institute, LLC
Morton Grove, Illinois, United States, 60053
Rockford Health Physicians
Rockford, Illinois, United States, 61103-3692
Rockford Orthopedic Associates
Rockford, Illinois, United States, 61114
Springfield Clinic
Springfield, Illinois, United States, 62702
Springfield Clinic - Clinical Research
Springfield, Illinois, United States, 62703
Deerbrook Medical Associates
Vernon Hills, Illinois, United States, 60061
United States, Indiana
Diagnostic Rheumatology And Research PC
Indianapolis, Indiana, United States, 46227
United States, Iowa
Physician's Clinic of Iowa, P.C.
Cedar Rapids, Iowa, United States, 52403
Medical Associates Clinic, PC
Dubuque, Iowa, United States, 52002
United States, Kansas
Kansas City Internal Medicine
Overland Park, Kansas, United States, 66209
Professional Research Network of Kansas, LLC
Wichita, Kansas, United States, 67203
Via Christi Clinic, P.A.
Wichita, Kansas, United States, 67208
United States, Kentucky
Bluegrass Community Research, Inc.
Lexington, Kentucky, United States, 40504
United States, Louisiana
Ochsner Clinic Foundation - Baton Rouge
Baton Rouge, Louisiana, United States, 70809
Louisiana State University Health Sciences Center
New Orleans, Louisiana, United States, 70115
United States, Maine
Rheumatology Associates
Portland, Maine, United States, 04102
United States, Maryland
Klein and Associates, MD, PA
Cumberland, Maryland, United States, 21502
The Arthritis Treatment Center
Frederick, Maryland, United States, 21702
The Center for Rheumatology and Bone Research
Wheaton, Maryland, United States, 20902
United States, Massachusetts
Clinical Research Center of Cape Cod, Inc.
Hyannis, Massachusetts, United States, 02601
Reliant Medical Group, Inc.
Worcester, Massachusetts, United States, 01605
Reliant Medical Group, Inc. at Worcester Medical Center
Worcester, Massachusetts, United States, 01608
United States, Michigan
Bronson Internal Medicine and Rheumatology
Battle Creek, Michigan, United States, 49015
QUEST Research Institiute
Bingham Farms, Michigan, United States, 48025
Borgess Research Institute
Kalamazoo, Michigan, United States, 49048
Farmbrook Radiology Associates
Southfield, Michigan, United States, 48034
United States, Minnesota
Arthritis and Rheumatology Consultants, P.A.
Edina, Minnesota, United States, 55435
United States, Mississippi
North Mississippi Medical Clinics, Inc.
Tupelo, Mississippi, United States, 38801
United States, Missouri
University Physicians - Woodrail Clinic
Columbia, Missouri, United States, 65203
University Of Missouri-Columbia
Columbia, Missouri, United States, 65212
United States, Nebraska
Physician Research Collaboration, LLC
Lincoln, Nebraska, United States, 68516
Clinical Pharmacology Study Group
Massachusetts, Nebraska, United States, 01605
Westroads Clinical Research, Inc.
Omaha, Nebraska, United States, 68114
Heartland Clinic Research, Inc.
Omaha, Nebraska, United States, 68134
United States, New Hampshire
Dartmouth-Hitchcock Medical Center
Lebanon, New Hampshire, United States, 03756
United States, New Jersey
Rheumatology Associates of North Jersey
Teaneck, New Jersey, United States, 07666
Arthritis, Rheumatic & Back Disease Associates
Voorhees, New Jersey, United States, 08043
United States, New York
The Center for Rheumatology, LLP
Albany, New York, United States, 12203
Regional Rheumatology Associates
Binghamton, New York, United States, 13905
Southern Tier Arthritis and Rheumatism
Olean, New York, United States, 14760
Buffalo Rheumatology and Medicine, PLLC
Orchard Park, New York, United States, 14127
AAIR Research Center
Rochester, New York, United States, 14618
United States, North Carolina
Asheville Rheumatology & Osteoporosis Research Associates, P.A.
Asheville, North Carolina, United States, 28801
Asheville Rheumatology & Osteoporosis Research Associates, PA
Asheville, North Carolina, United States, 28803
DJL Clinical Research, PLLC
Charlotte, North Carolina, United States, 28210
PMG Research Hickory, LLC
Hickory, North Carolina, United States, 28602
PMG Research of Hickory
Hickory, North Carolina, United States, USA 28602
Boice-Willis Clinic
Rocky Mount, North Carolina, United States, 27804
United States, North Dakota
Trinity Health Center - Medical Arts
Minot, North Dakota, United States, 58701
United States, Ohio
Cincinnati Rheumatic Disease Study Group, Inc.
Cincinnati, Ohio, United States, 45219
STAT Research, Inc.
Dayton, Ohio, United States, 45417
Office of David R. Mandel, MD, Inc.
Mayfield, Ohio, United States, 44143
United States, Oklahoma
Oklahoma Medical Research Foundation (OMRF)
Oklahoma City, Oklahoma, United States, 73104
Lynn Health Science Institute
Oklahoma City, Oklahoma, United States, 73112
United States, Pennsylvania
East Penn Rheumatology Associates, PC
Bethlehem, Pennsylvania, United States, 18015
Altoona Center for Clinical Research
Duncansville, Pennsylvania, United States, 16635
Rheumatic Disease Associates, Ltd.
Willow Grove, Pennsylvania, United States, 19090
Clinical Research Center of Reading LLP
Wyomissing, Pennsylvania, United States, 19610
United States, South Carolina
Piedmont Arthritis Clinic, PA
Greenville, South Carolina, United States, 29601
United States, Tennessee
Arthritis Associates, PLLC
Hixson, Tennessee, United States, 37343
Arthritis Clinic
Jackson, Tennessee, United States, 38305
West Tennessee Research Institute
Jackson, Tennessee, United States, 38305
Rheumatology Consultants, PLLC
Knoxville, Tennessee, United States, 37909-1907
Vanderbilt University Medical Center
Nashville, Tennessee, United States, 37203
United States, Texas
Office of John P. Lavery, MD, PA
Allen, Texas, United States, 75013
Austin Rheumatology Research, PA
Austin, Texas, United States, 78705
Arthritis Care and Diagnostic Center, P.A.
Dallas, Texas, United States, 75231
Baylor Research Institute
Dallas, Texas, United States, 75231
Metroplex Clinical Research Center
Dallas, Texas, United States, 75231
University of North Texas Health Science Center at Fort Worth
Fort Worth, Texas, United States, 76107
Accurate Clinical Research, Inc.
Houston, Texas, United States, 77034
Houston Institute for Clinical Research
Houston, Texas, United States, 77074
Arthritis and Osteoporosis Associates, LLP
Lubbock, Texas, United States, 79424
Southwest Rheumatology Research, LLC
Mesquite, Texas, United States, 75150
United States, Washington
Virginia Mason Medical Center
Seattle, Washington, United States, 98101
Seattle Rheumatology Associates
Seattle, Washington, United States, 98122
The Seattle Arthritis Clinic
Seattle, Washington, United States, 98133
Tacoma Center of Arthritis Research, PS
Tacoma, Washington, United States, 98405
The Vancouver Clinic, Inc. PS
Vancouver, Washington, United States, 98664
United States, West Virginia
Mountain State Clinical Research
Clarksburg, West Virginia, United States, 26301
United States, Wisconsin
Gundersen Clinic, Ltd
Onalaska, Wisconsin, United States, 54650
Argentina
OMI- Organizacion Medica de Investigacion
Buenos Aires, Caba, Argentina, C1015ABO
Centro de Investigaciones Reumatologicas y Osteologicas -CIRO
Buenos Aires, Caba, Argentina, C1114AAH
Hospital Sirio Libanes
Buenos Aires, Argentina, 1419AHN
OMI - Organización Médica de Investigación
Buenos Aires, Argentina, C1015ABO
Saint Dennis Medical Group S.A.
Buenos Aires, Argentina, C1034ACO
Hospital Sirio Libanes
Buenos Aires, Argentina, C1419AHN
Consultorios Reumatologicos Pampa
Buenos Aires, Argentina, C1428DZF
Australia, New South Wales
Optimus Clinical Research Pty. Ltd.
Kogarah, New South Wales, Australia, 2217
Australia, Queensland
Rheumatology Research
Cairns, Queensland, Australia, 4870
Rheumatology Research Unit Sunshine Coast
Maroochydore, Queensland, Australia, 4558
Australia, South Australia
Queen Elizabeth Hospital, Department of Rheumatology
Woodville, South Australia, Australia, 5011
Australia, Victoria
Emeritus Research
Malvern East, Victoria, Australia, 3145
Australia, Western Australia
Goatcher Clinical Research Unit
Perth, Western Australia, Australia, WA 6000
Australia
Royal North Shore Hospital
St Leonards, Australia, NSW2065
Austria
Medizinische Universitaet Wien / AKH
Wien, Austria, A-1090
Rheuma-Ordination Favoriten
Wien, Austria, A-1100
Sozialmedizinisches Zentrum Sued - Kaiser Franz Josef Spital
Wien, Austria, A-1100
Belgium
Universitair Ziekenhuis Gent - Reumatologie
Gent, Oost-vlaanderen, Belgium, 9000
AZ Groeninge
Kortrijk, Belgium, 8500
Centre Hospitalier Universitaire de Liège
Liège, Belgium, 4020
Bosnia and Herzegovina
University Clinical Center Sarajevo
Sarajevo, Bosnia and Herzegovina, 71000
Brazil
CIP - Centro Internacional de Pesquisa
Goiania, GO, Brazil, 74110-120
Centro de Estudos em Terapias Inovadoras
Curitiba, Paraná, Brazil, 80030-110
Centro de Estudos em Terapias Inovadoras
Curitiba, PR, Brazil, 80060-240
CCBR Brasil Centro de Pesquisas e Analises Clinicas Ltda
Rio de Janeiro, RJ, Brazil, 22271-100
Hospital de Clinicas de Porto Alegre
Porto Alegre, RS, Brazil, 90035-903
Hospital Sao Lucas da PUCRS
Porto Alegre, RS, Brazil, 90610-000
Hospital Alemao Oswaldo Cruz
Sao Paulo, SP, Brazil, 01323-903
Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo (HC-FMUSP)
Sao Paulo, SP, Brazil, 05403-010
IMA Brasil -Instituto de Pesquisa Clinica e Medicina Avancada
Sao Paulo, SP, Brazil, 05437-010
CEPIC - Centro Paulista de Investigacao Clinica e Servicos Medicos Ltda
Sao Paulo, Brazil, 04266-010
Bulgaria
Revmatologichen kabinet, DKTs Sveti Pantaleimon OOD
Pleven, Bulgaria, 5800
Revmatologichno Otdelenie, MBAL - Plovdiv
Plovdiv, Bulgaria, 4000
UMBAL Kaspela Plovdiv
Plovdiv, Bulgaria, 4002
MBAL Akta Medika OOD
Sevlievo, Bulgaria, 5400
Clinic of Cardiology and Rheumatology Military Medical Academy
Sofia, Bulgaria, 1606
Clinic of Rheumatology Multiprofile Hospital for Active treatment Sveti Ivan Rilski
Sofia, Bulgaria, 1612
MBAL Sveti Ivan Rilski Sofia
Sofia, Bulgaria, 1612
DKTs "Sveta Anna" Sofia, Konsultativen kabinet po Revmatologia
Sofia, Bulgaria, 1709
DKTs "Sveta Anna", Sofia / Diagnostic Consultative Center "Sveta Anna"
Sofia, Bulgaria, 1709
MOBAL "D-r Stefan Cherkezov" AD,
Veliko Tarnovo, Bulgaria, 5000
Canada, Alberta
Rheumatology Research Associates Ltd.
Edmonton, Alberta, Canada, T5M 0H4
Canada, British Columbia
Dr. Alice Klinkhoff, Inc.
Vancouver, British Columbia, Canada, V5Z 1L7
Percuro Clinical Research Limited
Victoria, British Columbia, Canada, V8V 3P9
Canada, Manitoba
Manitoba Clinic
Winnipeg, Manitoba, Canada, R3A 1M3
Canada, Newfoundland and Labrador
Nexus Clinical Research
St. John's, Newfoundland and Labrador, Canada, A1A 5E8
Canada, Ontario
Dr. William G. Bensen Medicine Professional Corporation
Hamilton, Ontario, Canada, L8N 1Y2
Office of Dr. Fernando Bianchi
Hamilton, Ontario, Canada, L8N 1Y2
Cividino Medicine Professional Corporation
Hamilton, Ontario, Canada, L8N 2B6
KW Musculoskeletal Research Inc.
Kitchener, Ontario, Canada, N2M 5N6
St Joseph's Health Centre
London, Ontario, Canada, N6A 4V2
Credit Valley Rheumatology
Missisauga, Ontario, Canada, L5M 2V8
The Arthritis Program Research Group Inc.
Newmarket, Ontario, Canada, L3Y 3R7
Rheumatology and Osteoporosis Clinic
Oakville, Ontario, Canada, L6M 4J2
Rheumatology Research Associates
Ottawa, Ontario, Canada, K1H 1A2
Niagara Peninsula Arthritis Centre
St. Catharines, Ontario, Canada, L2N 7E4
Clinical Research and Arthritis Centre
Windsor, Ontario, Canada, N8X 5A6
Canada, Quebec
Institut de Rhumatologie de Montreal
Montreal, Quebec, Canada, H2L 1S6
West Island Rheumatology Research Associates
Pointe Claire, Quebec, Canada, H9R 3J1
Centre de Recherche Musculo-Squelettique
Trois-Rivieres, Quebec, Canada, G8Z 1Y2
Canada, Saskatchewan
Arthritis Research Center, Royal University Hospital
Saskatoon, Saskatchewan, Canada, S7N 0W8
Canada
Groupe De Recherche En Rhumatologie Et Maladies Osseuses Inc.
Quebec, Canada, G1V 3M7
Centre de Recherche Saint-Louis
Quebec, Canada, G1W4R4
Chile
Consulta Privada Dra. Lucia Ponce
Temuco, IX Region, Chile, 4790928
Centro de Diagnostico y Tratamiento Hospital San Borja Arriaran
Santiago, Region Metropolitana, Chile, 8360156
Hospital Base Valdivia, Policlinico de Reumatologia
Valdivia, Region XIV, Chile, 5090145
Centro de Estudios Reumatologicos
Santiago, RM, Chile, 7501126
Consulta Privada Dra. Marta Aliste
Santiago, RM, Chile, 7510186
Clinica Santa Maria, Seccion Reumatologia
Providencia, Santiago, RM, Chile, 7530206
Hospital Regional de Rancagua
Rancagua, Chile, 2841959
Clinica Santa Maria
Santiago, Chile, 7530206
Estudios Clinicos V Region
Vina Del Mar, V Region, Chile, 2520997
China, Beijing
Beijing Chaoyang Hospital, Capital University of Medical Science
Beijing, Beijing, China, 100020
China, Guangdong
The Second Affiliated Hospital of Guangzhou Medical University
Guangzhou, Guangdong, China, 510260
The Third Affiliated Hospital of Sun Yat-Sen University
Guangzhou, Guangdong, China, 510630
China, Hubei
Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China, 430030
China, Hunan
Xiangya Hospital of Centre-south University
Changsha, Hunan, China, 410008
China, Shaanxi
Xijing Hospital, The Fourth Military Medical University
Xi'an, Shaanxi, China, 710032
China, Shandong
QiLu Hospital of Shandong University
Jinan, Shandong, China, 250012
Qingdao Municipal Hospital
Qingdao, Shandong, China, 266011
China, Shanghai
Shanghai Changzheng Hospital
Shanghai, Shanghai, China, 200003
China
Peking University People's Hospital/Rheumatology and Immunology Department
Beijing, China, 100044
PLA General Hospital
Beijing, China, 100853
Si Chuan Huaxi Hospital
Chengdu, China, 610041
The Second Affiliated Hospital of Zhejiang University School of Medicine
Hangzhou, China, 310009
Anhui Province Hospital
Hefei, China, 230001
An Hui Medical University 1st Hospital
Hefei, China, 230022
Jiangsu Province Hospital
Nanjing, China, 210029
Rheumatology and Immunology Dept., Renji Hospital Shanghai Jiao Tong University School of Medicine
Shanghai, China, 200001
Shanghai Changhai Hospital
Shanghai, China, 200433
The First Affiliated Hospital of Soochow University
Suzhou, China, 215006
"Department of Infectious Diseases & Immunology
Tianjin, China, 300052
Colombia
Centro de Reumatologia y Ortopedia S.A.S.
Barranquilla, Atlantico, Colombia
Riesgo de Fractura S.A.
Bogota D.C., Cundinamarca, Colombia
Centro de Investigacion en Reumatologia y Especialidades Medicas S.A.S CIREEM S.A.S
Bogota, D.C., Cundinamarca, Colombia
Servimed S.A.S.
Bucaramanga, Santander, Colombia, 680003
Costa Rica
Centro de Reumatologia y Osteoporosis, Cartago
Cartago, Costa Rica
Hospital Cima San Jose
San Jose, Costa Rica, 00000
Hospital Cima San Jose
San Jose, Costa Rica
Oficina Privada Del Colegio deMedicos
San Jose, Costa Rica
Croatia
University Hospital Center Osijek
Osijek, Croatia, 31000
University Hospital Split, Department for Internal Medicine, Division of Clinical Rheumatology
Split, Croatia, 21000
Clinical Hospital "Sveti Duh"
Zagreb, Croatia, 10 000
University Hospital Center "Zagreb"
Zagreb, Croatia, 10000
University Hospital Center Zagreb
Zagreb, Croatia, 10000
Czechia
X-MEDICA s.r.o.
Brno, Czechia, 61300
Revmacentrum MUDr. Mostera, s.r.o.
Brno, Czechia, 615 00
Fakultni Nemocnice Brno, Interni hematoonkologicka klinika
Brno, Czechia, 625 00
Fakultni nemocnice u sv. Anny v Brne
Brno, Czechia, 656 91
HESTE s.r.o. Revmatologie
Ceska Lipa, Czechia, 470 01
MEDIPONT Plus sro
Ceske Budejovice, Czechia, 370 01
L.K.N. Arthrocentrum, s.r.o.
Hlucin, Czechia, 748 01
ARTMEDI UPD s r.o
Hostivice, Czechia, 253 01
Fakultni nemocnice Hradec Kralove
Hradec Kralove, Czechia, 50005
Revmatologicka ambulance
Ostrava, Czechia, 70800
ARTHROMED, s. r. o. Revmatologicka ambulance
Pardubice, Czechia, 530 02
Affidea Praha, s.r.o.
Praha 11 - Chodov, Czechia, 148 00
Revmatologicky ustav
Praha 2, Czechia, 12850
Revmatologicka ambulance
Praha 4, Czechia, 140 00
Fakultni Thomayerova nemocnice s poliklinikou
Praha 4, Czechia, 140 59
Nuselska poliklinika RTG
Praha 4, Czechia, 14000
Revmatologicka ambulance
Praha 4, Czechia, 14000
Nemocnice Atlas, a.s.
Zlin, Czechia, 760 01
PV-Medical s.r.o.
Zlin, Czechia, 760 01
Denmark
Frederiksberg Hospital
Frederiksberg, Denmark, 2000
Dominican Republic
Hospital Central de las Fuerzas Armadas
Santo Domingo, Dominican Republic, 10119
Finland
Helsingin Reumakeskus Oy
Helsinki, Finland, 00120
Kiljavan Laaketutkimus Oy
Hyvinkaa, Finland, 05800
TAYS/Reumakeskus/Finn-Medi 1
Tampere, Finland, 33520
France
Hopital Nord
Amiens, France, 80000
Hôpital Nord
Amiens, France, 80000
*CHR Hopital Porte Madeleine IPROS
Orleans, France, 45000
CHR ORLEANS - Service IPROS
Orleans, France, 45032
Hôpital Saint-Antoine
Paris, France, 75012
Hopital Cochin
Paris, France, 75014
Germany
Privat-Praxis
Aachen, Germany, 52064
Charite Campus Mitte, Medizinische Klinik mit Schwerpunkt Rheumatologie und Klinische Immunologie
Berlin, Germany, 10117
Schlosspark-Klinik Innere Medizin II, Rheumatologie
Berlin, Germany, 14059
Ambulantes Rheumazentrum Dr Soerensen
Berlin, Germany, 14163
Krankenhaus Friedrichstadt, I. Medizinische Klinik
Dresden, Germany, 01067
Studienambulanz Universitaetsklinikum Erlangen Medizinische Klinik 3
Erlangen, Germany, 91054
J.W.-Goethe-Universitaetsklinik, Medizinische Klinik II, Abteilung fuer Rheumatologie
Frankfurt am Main, Germany, 60590
Schwerpunktpraxis Rheumatologie
Halle, Germany, 06108
Schoen Klinik Hamburg-Eilbek
Hamburg, Germany, 22081
Rheumazentrum Ruhrgebiet
Herne, Germany, 44649
Universitaetsklinikum Koeln Klinik I fuer Innere Medizin, Haus 16, 1. OG, Raum 1.008
Koeln, Germany, 50937
Universitaetsklinik Leipzig, Klinik fur Gastroenterologie und Rheumatologie, Sektion Rheumatologie
Leipzig, Germany, 04103
Universitaetsklinikum Leipzig
Leipzig, Germany, 04103
Klinikum der Universitaet Muenchen, Campus Innenstadt, Rheuma-Einheit
Muenchen, Germany, 80336
Arztpraxis, Internist - Rheumatologie
Nuernberg, Germany, 90429
Rheumaforschung- Studienambulanz
Ratingen, Germany, 40882
Schwerpunktpraxis fuer Rheumatologie
Rheine, Germany, 48431
Universitaetsklinikum Wuerzburg
Wuerzburg, Germany, 97080
Greece
General Hospital Euromedica "KYANOUS STAVROS"
Thessaloniki, Greece, 54636
424 General Army Hospital
Thessaloniki, Greece, 56429
Hungary
Drug Research Center Kft
Balatonfured, Hungary, 8230
Orszagos Reumatologiai Es Fizioterapias Intezet
Budapest, Hungary, 1023
Revita Reumatologiai Rendelo
Budapest, Hungary, 1027
Synexus Magyarorszag Kft.
Budapest, Hungary, H-1036
MAV Korhaz es Rendelointezet, Reumatologiai szakrendeles
Szolnok, Hungary, 5000
India
Mahavir Hospital & Research Center
Hyderabad, Andhra Pradesh, India, 500 004
Rheumatic Diseases Clinic
Ahmedabad, Gujarat, India, 380009
Shalby Hospitals
Ahmedabad, Gujarat, India, 380015
Chanre Rheumatology and Immunology Center and Research
Bangalore, Karnataka, India, 560 003
St. John's Medical College and Hospital.
Bangalore, Karnataka, India, 560 034
Shirdi Sai Hospital
Bangalore, Karnataka, India, 560 054
Chanre Rheumatology & Immunology Center & Research
Bangalore, Karnataka, India, 560 079
Arthritis Research and Care Foundation Centre for Rheumatic Diseases
Pune, Maharashtra, India, 411 001
Jehangir Clinical Development Centre Pvt. Ltd.
Pune, Maharashtra, India, 411001
Krishna Institute of Medical Sciences Ltd
Secunderabad, Telangana, India, 500 003
Ireland
St. Vincent's University Hospital
Elm Park, Dublin, Ireland
Italy
A.O.U. Careggi - SOD Medicina Interna 1 e Reumatologia
Firenze, FI, Italy, 50139
U.O. Clinica Reumatologica
Genova, Italy, 16132
Korea, Republic of
Inha University Hospital
Jung-gu, Incheon, Korea, Republic of, 22332
Eulji University Hospital
Daejeon, Republic OF Korea, Korea, Republic of, 35233
Dong-A University Hospital
Busan, Korea, Republic of, 49201
Daegu Catholic University Medical Center
Daegu, Korea, Republic of, 42472
Chonnam National University Hospital
Gwangju, Korea, Republic of, 61469
Gangnam Severance Hospital
Seoul,, Korea, Republic of, 06273
Seoul National University Hospital
Seoul, Korea, Republic of, 03080
Yonsei University Health System
Seoul, Korea, Republic of, 03722
Hanyang University Hospital
Seoul, Korea, Republic of, 04763
Konkuk University Medical Center
Seoul, Korea, Republic of, 05030
Asan Medical Center-University of Ulsan College of Medicine
Seoul, Korea, Republic of, 05505
Asan Medical Center
Seoul, Korea, Republic of, 05505
Gangnam Severance Hospital-Yonsei University Health System
Seoul, Korea, Republic of, 06273
Seoul St. Mary's Hospital-The Catholic University of Korea
Seoul, Korea, Republic of, 06591
Malaysia
Hospital Tuanku Ja'afar
Seremban, Negeri Sembilan, Malaysia, 70300
Queen Elizabeth Hospital
Kota Kinabalu, Sabah, Malaysia, 88586
Sarawak General Hospital
Kuching, Sarawak, Malaysia, 93586
Hospital Selayang
Batu Caves, Selangor, Malaysia, 68100
Sunway Medical Centre
Petaling Jaya, Selangor, Malaysia, 46150
Subang Jaya Medical Centre
Subang Jaya, Selangor, Malaysia, 47500
Hospital Putrajaya, Dept. of Medicine
Putrajaya, Wilayah Persekutuan, Malaysia, 62250
Mexico
Centro de Investigacion del Noroeste
Tijuana, BAJA California Norte, Mexico, 22010
Unidad de Enfermedades Reumaticas y Cronico Degenerativas SC
Torreon, Coahuila, Mexico, 27000
Hospital Angeles del Pedregal
Mexico, DF, Mexico, 10700
Centro Medico Toluca
Metepec, Estado DE Mexico, Mexico, 52140
Centro Integral en Reumatologia, SA de CV
Guadalajara, Jalisco, Mexico, 44160
Unidad de Investigacion en Enfermedades Cronico Degenerativas
Guadalajara, Jalisco, Mexico, 44620
Centro de Investigacion Clinica Especializada, SC
Coyoacan, Mexico D.F., Mexico, 04030
Centro de Investigacion Clinica de Morelia
Morelia, Michoacan, Mexico, 58070
Clinica de Enfermedades Cronicas y Procedimientos Especiales SC
Morelia, Michoacan, Mexico, 58249
Fundacion El Hospitalito
Cuernavaca, Morelos, Mexico, 62170
Hospital Universitario Doctor Jose Eleuterio Gonzalez
Monterrey, Nuevo LEON, Mexico, 64020
Unidad Reumatologica Las Americas SCP
Merida, Yucatan, Mexico, 97000
Investigacion y Biomedica de Chihuahua, SC
Chihuahua, Mexico, 31000
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Mexico City, Mexico, 14080
Hospital Angeles Mocel
Mexico, D.F., Mexico, 11850
Centro Reumatologico Queretaro
Queretaro, Mexico, 76178
Centro de Alta Especialidad en Reumatologia e Investigacion del Potosi, S.C.
San Luis Potosi, Mexico, 78213
Hospital Central Dr Ignacio Morones Prieto Unidad Regional de Reumatologia y Osteoporosis
San Luis Potosi, Mexico, 78240
New Zealand
The Canterbury Geriatric Medical Research Trust, c/- The Princess Margaret Hospital
Christchurch, New Zealand, 8022
Waikato Hospital, Rheumatology
Hamilton, New Zealand, 3240
Clinical Trials Unit, Timaru Hospital
Timaru, New Zealand, 7910
Peru
Hospital Nacional IV Alberto Sabogal Sologuren
Callao, Peru, C-02
Centro Medico Corpac/Investigaciones en Reumatologia
Lima, Peru, L-27
Instituto Peruano del Hueso y la Articulacion SAC-Privado-Lima/Centro de Investigacion IPHAR
Lima, Peru, L-27
Philippines
Mary Mediatrix Medical Center
Lipa City, Batangas, Philippines, 4217
De La Salle University Health Sciences Campus Clinical Epidemiology Unit
Dasmarinas, Cavite, Philippines, 4114
Angeles University Foundation Medical Center
Angeles City, Pampanga, Philippines, 2009
Chong Hua Hospital
Cebu City, Philippines, 6000
Southern Philippine Medical Center
Davao City, Philippines, 8000
University of Perpetual Help Rizal Dalta Medical Center
Las Piñas City, Philippines, 1742
University of Santo Tomas Hospital
Manila, Philippines, 1008
Poland
"ZDROWIE OSTEO-MEDIC" s.c. Lidia I Artur Racewicz, Agnieszka I Jerzy Supronik
Bialystok, Poland, 15-351
ClinicMed Badurski i wspolnicy Spolka Jawna
Bialystok, Poland, 15-879
NSZOZ Medicus II
Cieszyn, Poland, 43400
Szpital im. Teodora Dunina
Koscian, Poland, 64-000
Krakowskie Centrum Medyczne NZOZ
Krakow, Poland, 31-501
Centrum Badan Klinicznych s.c. Wieslawa Porawska, Lukasz Porawski
Poznan, Poland, 60-773
Wojewodzki Zespol Reumatologiczny im. dr Jadwigi Titz-Kosko
Sopot, Poland, 81-759
Nzoz "Nasz Lekarz"
Torun, Poland, 87-100
Synexus Polska Sp. z o.o. Oddzial w Warszawie
Warszawa, Poland, 01-192
Rheuma-Medicus - Specjalistyczne Centrum Reumatologii i Osteoporozy
Warszawa, Poland, 02-118
SYNEXUS Polska Sp. z.o.o.
Wroclaw, Poland, 50-088
Puerto Rico
Ponce School Of Medicine
Ponce, Puerto Rico, 00716
Edificio Parra
Ponce, Puerto Rico, 00717-1321
Mindful Medical Research
San Juan, Puerto Rico, 00918
Romania
Spitalul Clinic "Sf. Maria"
Bucharest, Romania, 011172
Spitalul Clinic De Recuperare
Iasi, Romania, 700661
Russian Federation
City Clinical Hospital # 1
Novosibirsk City, Novosibirsk Region, Russian Federation, 630047
"Consultative Diagnostic Rheumatology Center ""Healthy Joints"", LLC"
Novosibirsk City, Novosibirsk Region, Russian Federation, 630091
State Healthcare Institution City Hospital # 40 of Administrative Health Resort District
Saint-Petersburg, Sestroretsk, Russia, Russian Federation, 197706
Smolensk State Medical Academy
Smolensk, Smolensk Region, Russian Federation, 214019
State Healthcare Institution Regional Clinical Hospital
Barnaul, Russian Federation, 656024
State Healthcare Institution
Ekaterinburg, Russian Federation, 620102
State Educational Institution of Higher Professional Education Ural State Medical Academy of Federal
Ekaterinburg, Russian Federation, 620149
State Educational Institution of Higher Professional Education
Ekaterinburg, Russian Federation, 620149
Ltd.Medical Association "Novaya Bolnitsa"
Ekaterinburg, Russian Federation, 620219
State Healthcare Institution Regional Clinical Hospital for War Veterans
Kemerovo, Russian Federation, 650099
Russian State Medical University Moscow Faculty City Clinical Hospital #4
Moscow, Russian Federation, 115093
Rheumatology Research Institute of Russian Academy of Medical Sciences
Moscow, Russian Federation, 115522
GUZ Republican Hospital n.a. Baranov
Petrozavodsk, Russian Federation, 185019
Federal North-West Medical Research Centre
Saint-Petersburg, Russian Federation, 197341
Saint-Petersburg State Budgetary Healthcare Institution "Clinical Rheumathology Hospital #25"
St. Petersburg,, Russian Federation, 190068
Clinical Hospital #122 named after L.G. Sokolov of the Federal Medical-Biological Agency
St. Petersburg, Russian Federation, 194291
St. Petersburg State Institution of Healthcare Consultative-diagnostic Center #85
St. Petersburg, Russian Federation, 198260
Regional State Budget Institution Of Healthcare
Tomsk, Russian Federation, 634063
Regional State Budgetary Healthcare Institution of Tomsk Regional Clinical Hospital
Tomsk, Russian Federation, 634063
Slovakia
Reumatologicka ambulancia, Poliklinika Ruzinov
Bratislava, Slovakia, 82606
NOVAPHARM s.r.o -Zeleznicna NaP, Reumatologicka ambulancia
Bratislava, Slovakia, 832 99
AAGS, s.r.o. , nestatne zdravotnicke zariadenie
Dunajska Streda, Slovakia, 92901
Interna a reumatologicka ambulancia
Kosice, Slovakia, 040 01
Ecclesia, s.r.o Reumatologicka ambulancia
Nove Zamky, Slovakia, 94001
Narodny Ustav Reumatickych Chorob
Piestany, Slovakia, 92112
Reumatologicka ambulancia, MUDr. Zuzana Cizmarikova, s.r.o.
Poprad, Slovakia, 058 01
Reumatologicka ambulancia, REUMEX, s.r.o.
Rimavska Sobota, Slovakia, 979 01
Reumatologicka ambulancia, Nestatne zdravotnicke zariadenie
Senica, Slovakia, 905 01
Nestatna reumatologicka ambulancia, MUDr. Pavol Polak s.r.o.
Zilina, Slovakia, 010 01
Spain
Hospital Nuestra Senora de la Esperanza
Santiago De Compostela, A Coruna, Spain, 15705
Hospital Clinico Universitario de Santiago
Santiago de Compostela, A Coruna, Spain, 15706
Hospital de Merida
Merida, Badajoz, Spain, 06800
Hospital Universitario Marques de Valdecilla
Santander, Cantabria, Spain, 39008
Hospital Universitario Cruces
Barakaldo, Vizcaya, Spain, 48903
Hospital de Basurto
Bilbao, Vizcaya, Spain, 48013
Hospital Del Mar
Barcelona, Spain, 08003
Complejo Hospitalario Universitario A Coruna
Coruna, Spain, 15006
Hospital Universitario 12 de Octubre
Madrid, Spain, 28041
Hospital Universitario De La Paz
Madrid, Spain, 28046
Hospital Civil. Hospital Regional Universitario Carlos Haya
Malaga, Spain, 29009
Hospital Universitario Virgen Macarena
Sevilla, Spain, 41009
Hospital Nuestra Señora de Valme
Sevilla, Spain, 41014
Hospital El Tomillar
Sevilla, Spain, 41700
Hospital Universitari i Politecnic La Fe de Valencia
Valencia, Spain, 46026
Sweden
Falu lasarett
Falun, Sweden, 791 82
Lanssjukhuset Ryhov
Jonkoping, Sweden, 551 85
Skanes Universitetssjukhus i Malmo Reumamottagningen
Malmo, Sweden, 205 02
Sundsvalls Sjukhus
Sundsvall, Sweden, 851 86
Norrlands Universitetssjukhus
Umea, Sweden, 901 85
Akademiska University Hospital
Uppsala, Sweden, 75185
Taiwan
Chang Gung Medical Foundation-
Niao Sung Hsiang, Kaohsiung County, Taiwan, 833
Chang Gung Medical Foundation-Linkou Branch
Kwei-Shan, Taoyuan County, Taiwan, 333
Changhua Christian Hospital
Changhua, Taiwan, 500
Kaohsiung Medical University Chung-Ho Memorial Hospital
Kaohsiung, Taiwan, 807
Kaohsiung Veterans General Hospital
Kaohsiung, Taiwan, 813
Taichung Veterans General Hospital
Taichung, Taiwan, 407
National Cheng Kung University Hospital
Tainan, Taiwan, 704
National Taiwan University Hospital
Taipei, Taiwan, 100
Taipei Veterans General Hospital
Taipei, Taiwan, 112
Thailand
Rheumatology Unit, Department of Internal Medicine, Phramongkutklao Hospital
Rajathevee, Bangkok, Thailand, 10400
Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine,
Amphoe Mueang, Chiang MAI, Thailand, 50200
Division of Allergy-Immunology-Rheumatology, Department of Medicine, Faculty of Medicine
Muang District, Khonkaen, Thailand, 40002
Rheumatology Unit, Department of Internal Medicine, Rajavithi Hospital
Bangkok, Thailand, 10400
Siriraj Hospital, Mahidol University
Bangkok, Thailand, 10700
Turkey
Ege University Medical Faculty
Bornova, Izmir, Turkey, 35100
Hacettepe University Medical Faculty
Ankara, Turkey, 06100
Dokuz Eylul Universitesi Arastirma Uygulama Hastanesi
Izmir, Turkey, 35340
Ukraine
Crimean Republican Institution "Clinical Territorial Medical Association "University Clinic",
Simferopol, Crimea, Ukraine, 95017
Municipal Establishment of Health Care "Kharkiv City Clinical Hospital #8", Dept. of Rheumatology
Kharkiv, Ukraine, 61178
State Institution Republican Clinical Hospital of the Ministry of Health of Ukraine
Kyiv, Ukraine, 04053
State Establishment "Institute of Gerontology of NAMS of Ukraine n.a. D.F. Chebotareva"
Kyiv, Ukraine, 04114
Municipal City Clinical Hospital #4, Policlinic Care
Lviv, Ukraine, 79011
"Multifield Medical Center of Odesa National Medical University ""University Clinic #1"""
Odesa, Ukraine, 65026
Multifield Medical Center of Odesa National Medical University "University Clinic #1"
Odesa, Ukraine, 65026
CRIMEAN Republican Institution, "Clinical Hospital n.a. M.O. Semashko"
Simferopol Crimea, Ukraine, 95017
Vinnitsa Regional Clinical Hospital n.a. Pirogov
Vinnitsa, Ukraine, 21018
Municipal Establishment "City Hospital#7of Zaporizhzhia State Medical University
Zaporizhzhia, Ukraine, 69118
United Kingdom
Dudley Group of Hospitals NHS Trust
Dudley, WEST Midlands, United Kingdom, DY1 2HQ
The Royal Wolverhampton NHS Trust
Cannock, United Kingdom, WS11 5XY
Royal Victoria Infirmary
Newcastle Upon Tyne, United Kingdom, NE1 4LP
Wirral University Teaching Hospital NHS Foundation Trust-Arrowe Park Hospital
Wirral, United Kingdom, CH49 5PE

Sponsors and Collaborators

Pfizer

Investigators

Layout table for investigator information

Study Director:	Pfizer CT.gov Call Center	Pfizer

More Information

Additional Information:

To obtain contact information for a study center near you, click here. This link exits the ClinicalTrials.gov site

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Mueller RB, Schulze-Koops H, Furst DE, Cohen SB, Kwok K, Wang L, Killeen T, von Kempis J. Effect of dose adjustments on the efficacy and safety of tofacitinib in patients with rheumatoid arthritis: a post hoc analysis of an open-label, long-term extension study (ORAL Sequel). Clin Rheumatol. 2022 Apr;41(4):1045-1055. doi: 10.1007/s10067-021-05908-z. Epub 2022 Jan 1.

Winthrop KL, Curtis JR, Yamaoka K, Lee EB, Hirose T, Rivas JL, Kwok K, Burmester GR. Clinical Management of Herpes Zoster in Patients With Rheumatoid Arthritis or Psoriatic Arthritis Receiving Tofacitinib Treatment. Rheumatol Ther. 2022 Feb;9(1):243-263. doi: 10.1007/s40744-021-00390-0. Epub 2021 Dec 6.

Cohen SB, Tanaka Y, Mariette X, Curtis JR, Lee EB, Nash P, Winthrop KL, Charles-Schoeman C, Wang L, Chen C, Kwok K, Biswas P, Shapiro A, Madsen A, Wollenhaupt J. Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programme. RMD Open. 2020 Oct;6(3):e001395. doi: 10.1136/rmdopen-2020-001395.

van der Heijde D, Landewe RBM, Wollenhaupt J, Strengholt S, Terry K, Kwok K, Wang L, Cohen S. Assessment of radiographic progression in patients with rheumatoid arthritis treated with tofacitinib in long-term studies. Rheumatology (Oxford). 2021 Apr 6;60(4):1708-1716. doi: 10.1093/rheumatology/keaa476.

Panaccione R, Isaacs JD, Chen LA, Wang W, Marren A, Kwok K, Wang L, Chan G, Su C. Characterization of Creatine Kinase Levels in Tofacitinib-Treated Patients with Ulcerative Colitis: Results from Clinical Trials. Dig Dis Sci. 2021 Aug;66(8):2732-2743. doi: 10.1007/s10620-020-06560-4. Epub 2020 Aug 20. Erratum In: Dig Dis Sci. 2020 Oct 10;:

Kaine J, Tesser J, Takiya L, DeMasi R, Wang L, Snyder M, Soma K, Fan H, Bandi V, Wollenhaupt J. Re-establishment of efficacy of tofacitinib, an oral JAK inhibitor, after temporary discontinuation in patients with rheumatoid arthritis. Clin Rheumatol. 2020 Jul;39(7):2127-2137. doi: 10.1007/s10067-020-04956-1. Epub 2020 Feb 12.

Wollenhaupt J, Lee EB, Curtis JR, Silverfield J, Terry K, Soma K, Mojcik C, DeMasi R, Strengholt S, Kwok K, Lazariciu I, Wang L, Cohen S. Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study. Arthritis Res Ther. 2019 Apr 5;21(1):89. doi: 10.1186/s13075-019-1866-2.

Li ZG, Liu Y, Xu HJ, Chen ZW, Bao CD, Gu JR, Zhao DB, An Y, Hwang LJ, Wang L, Kremer J, Wu QZ. Efficacy and Safety of Tofacitinib in Chinese Patients with Rheumatoid Arthritis. Chin Med J (Engl). 2018 Nov 20;131(22):2683-2692. doi: 10.4103/0366-6999.245157.

Hall S, Nash P, Rischmueller M, Bossingham D, Bird P, Cook N, Witcombe D, Soma K, Kwok K, Thirunavukkarasu K. Tofacitinib, an Oral Janus Kinase Inhibitor: Pooled Efficacy and Safety Analyses in an Australian Rheumatoid Arthritis Population. Rheumatol Ther. 2018 Dec;5(2):383-401. doi: 10.1007/s40744-018-0118-2. Epub 2018 Jun 11.

Fleischmann R, Wollenhaupt J, Takiya L, Maniccia A, Kwok K, Wang L, van Vollenhoven RF. Safety and maintenance of response for tofacitinib monotherapy and combination therapy in rheumatoid arthritis: an analysis of pooled data from open-label long-term extension studies. RMD Open. 2017 Dec 18;3(2):e000491. doi: 10.1136/rmdopen-2017-000491. eCollection 2017.

Fleischmann R, Wollenhaupt J, Cohen S, Wang L, Fan H, Bandi V, Andrews J, Takiya L, Bananis E, Weinblatt ME. Effect of Discontinuation or Initiation of Methotrexate or Glucocorticoids on Tofacitinib Efficacy in Patients with Rheumatoid Arthritis: A Post Hoc Analysis. Rheumatol Ther. 2018 Jun;5(1):203-214. doi: 10.1007/s40744-018-0093-7. Epub 2018 Feb 7.

Mariette X, Chen C, Biswas P, Kwok K, Boy MG. Lymphoma in the Tofacitinib Rheumatoid Arthritis Clinical Development Program. Arthritis Care Res (Hoboken). 2018 May;70(5):685-694. doi: 10.1002/acr.23421. Epub 2018 Apr 2.

Cohen SB, Tanaka Y, Mariette X, Curtis JR, Lee EB, Nash P, Winthrop KL, Charles-Schoeman C, Thirunavukkarasu K, DeMasi R, Geier J, Kwok K, Wang L, Riese R, Wollenhaupt J. Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials. Ann Rheum Dis. 2017 Jul;76(7):1253-1262. doi: 10.1136/annrheumdis-2016-210457. Epub 2017 Jan 31.

Genovese MC, van Vollenhoven RF, Wilkinson B, Wang L, Zwillich SH, Gruben D, Biswas P, Riese R, Takiya L, Jones TV. Switching from adalimumab to tofacitinib in the treatment of patients with rheumatoid arthritis. Arthritis Res Ther. 2016 Jun 23;18:145. doi: 10.1186/s13075-016-1049-3.

Winthrop KL, Silverfield J, Racewicz A, Neal J, Lee EB, Hrycaj P, Gomez-Reino J, Soma K, Mebus C, Wilkinson B, Hodge J, Fan H, Wang T, Bingham CO 3rd. The effect of tofacitinib on pneumococcal and influenza vaccine responses in rheumatoid arthritis. Ann Rheum Dis. 2016 Apr;75(4):687-95. doi: 10.1136/annrheumdis-2014-207191. Epub 2015 Mar 20.

Boyle DL, Soma K, Hodge J, Kavanaugh A, Mandel D, Mease P, Shurmur R, Singhal AK, Wei N, Rosengren S, Kaplan I, Krishnaswami S, Luo Z, Bradley J, Firestein GS. The JAK inhibitor tofacitinib suppresses synovial JAK1-STAT signalling in rheumatoid arthritis. Ann Rheum Dis. 2015 Jun;74(6):1311-6. doi: 10.1136/annrheumdis-2014-206028. Epub 2014 Nov 14.

Layout table for additonal information

Responsible Party:	Pfizer
ClinicalTrials.gov Identifier:	NCT00413699
Other Study ID Numbers:	A3921024 2006-005035-19 ( EudraCT Number )
First Posted:	December 20, 2006 Key Record Dates
Results First Posted:	March 27, 2018
Last Update Posted:	October 30, 2018
Last Verified:	October 2018

Keywords provided by Pfizer:


long-term open-label safety

Additional relevant MeSH terms:

Layout table for MeSH terms

Arthritis Arthritis, Rheumatoid Joint Diseases Musculoskeletal Diseases Rheumatic Diseases Connective Tissue Diseases Autoimmune Diseases	Immune System Diseases Tofacitinib Janus Kinase Inhibitors Protein Kinase Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action

To Top